This is a working overview of nuclear receptor, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2026-07-25. Anything still debated is marked as such rather than presented as settled.
Quality control for research materials includes identity confirmation by nuclear magnetic resonance and purity assessment by high-performance liquid chromatography. Mass spectrometry provides molecular weight confirmation and can detect related impurities. Purchasers should request a certificate of analysis that lists lot-specific data. Online products advertised for human use often lack such documentation. Distinguishing legitimate research material from mislabeled or contaminated samples is a recurring challenge in independent testing, and independent laboratories may use orthogonal methods to verify identity.
Detection of SR9009 in biological samples usually relies on liquid chromatography coupled to tandem mass spectrometry. This approach separates the compound from matrix components and identifies it by mass transitions. Because SR9009 can undergo metabolism, laboratories often look for both parent drug and specific metabolites. Sample preparation may involve protein precipitation or solid-phase extraction. Method validation examines sensitivity, carryover, and interference from related substances, and reference standards are required for accurate calibration.
SR9009 is frequently discussed alongside other REV-ERB ligands, including synthetic agonists and natural heme-related molecules. Its selectivity for REV-ERB over related nuclear receptors has been measured in binding and reporter assays, though off-target activity at higher concentrations is possible. The compound is prohibited in sport by the World Anti-Doping Agency, and it is not approved for any medical use in major jurisdictions. Products sold online may be labeled as research chemicals, and their identity and purity are not guaranteed by regulatory review.
SR9009 is a synthetic small molecule that acts on the nuclear receptors REV-ERBα and REV-ERBβ. These receptors are part of the circadian clock machinery and normally repress transcription of certain target genes. In laboratory research, SR9009 is used as a chemical tool to study how REV-ERB activity influences metabolism, inflammation, and daily biological rhythms. The compound is not an approved medicine, and its effects in humans remain largely uncharacterized. It is often described as an investigational agent rather than a therapeutic product.
REV-ERB proteins typically suppress gene expression by recruiting corepressor complexes to DNA response elements. SR9009 binds these receptors and strengthens that repressive action in cell-based assays. Studies in rodents have reported changes in lipid handling, mitochondrial function, and exercise capacity after treatment. Such findings are often cited as evidence for metabolic effects, but species differences and limited pharmacokinetic data make direct translation to humans uncertain. Researchers continue to examine which effects are robust and which depend on specific experimental conditions.
| Property | Value | Notes |
|---|---|---|
| Typical storage temperature | -20 °C or lower | Desiccated and protected from light |
| Common analytical method | LC-MS/MS | Detects parent drug and metabolites |
| Solubility class | Lipophilic; soluble in organic solvents | Low aqueous solubility |
| Molecular weight | 437.94 g/mol | Calculated from reported formula |
| Synonyms | SR9009; REV-ERB agonist | Code name used in scientific literature |
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Most published work on SR9009 consists of preclinical studies. It is widely sold as a research chemical, a category that does not imply safety, efficacy, or pharmaceutical-grade quality. Sports anti-doping organizations have listed SR9009 as a prohibited substance, and its presence in an athlete sample can lead to sanctions. Legal status differs by country; in several jurisdictions it is not approved for human consumption and may be treated as an unapproved new drug.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not a steroid, peptide, or natural hormone. In scientific literature, it appears under the code SR9009 and in non-scientific contexts as Stenabolic. The compound was identified through chemical screening efforts aimed at targeting circadian clock components. Its status remains investigational, and no regulatory agency has approved it as a human medicine.
REV-ERB proteins help regulate daily cycles in gene expression, including genes tied to lipid and glucose metabolism. SR9009 binds these receptors and alters their activity in cell and animal experiments. Consequences observed in rodents include changes in skeletal muscle oxidative capacity, blood lipid levels, and exercise performance. The precise chain from receptor occupancy to whole-body effects is still an active area of study. Human responses cannot be assumed from rodent data.
Regulatory status varies by country and intended use. Major drug agencies have not granted marketing authorization for SR9009 as a medicine, and it is not listed as a controlled substance in many jurisdictions. It is often sold as a research chemical, a category that may fall outside pharmaceutical manufacturing rules. Buyers should verify local laws and supplier documentation, including certificates of analysis. The lack of standardized quality controls raises concerns about identity, purity, and actual content in products marketed online.
In laboratory settings, SR9009 is commonly identified by its molecular structure and its interaction with REV-ERB receptors. Vendors may list it under synonyms such as Stenabolic or REV-ERB agonist, but those names do not define purity or identity. Analytical confirmation typically uses high-performance liquid chromatography with ultraviolet detection or liquid chromatography–mass spectrometry. A reference standard is needed to compare retention time and mass spectrum, because the compound can be confused with related research chemicals.
Handling practices for SR9009 focus on minimizing degradation and contamination. The solid is generally stored desiccated at or below -20 °C, protected from light and moisture. Stock solutions are often prepared in dimethyl sulfoxide or ethanol, then aliquoted to avoid repeated freeze–thaw cycles. Aqueous solubility is low, so formulations for animal studies may require cosolvents or suspending agents. Personnel should follow institutional chemical safety procedures, because toxicological data for humans are incomplete.
== Taxonomy == The Wagler's pit viper has undergone much taxonomic reclassification over the years and was previously placed in the genus Trimeresurus. However, its distinctly different morphology and venom characteristics set it apart, so that eventually a new genus was erected in which it was placed together with Hutton's viper, Tropidolaemus huttoni.
Plague of Justinian, from 541 to 542, killed between 50% and 60% of Europe's population. The Black Death of 1347 to 1352 killed 25 million in Europe over five years. The plague reduced the old world population from an estimated 450 million to between 350 and 375 million in the 14th century. The introduction of smallpox, measles, and typhus to the areas of Central and South America by European explorers during the 15th and 16th centuries caused pandemics among the native inhabitants. Between 1518 and 1568 disease pandemics are said to have caused the population of Mexico to fall from 20 million to 3 million. The first European influenza epidemic occurred between 1556 and 1560, with an estimated mortality rate of 20%. Smallpox killed an estimated 60 million Europeans during the 18th century (approximately 400,000 per year). Up to 30% of those infected, including 80% of the children under 5 years of age, died from the disease, and one-third of the survivors went blind. In the 19th century, tuberculosis killed an estimated one-quarter of the adult population of Europe; by 1918 one in six deaths in France were still caused by TB. The Influenza Pandemic of 1918 (or the Spanish flu) killed 25–50 million people (about 2% of world population of 1.7 billion). Today Influenza kills about 250,000 to 500,000 worldwide each year. In 2021, COVID-19 emerged as a major global health crisis, directly causing 8.7 million deaths, making it one of the leading causes of mortality worldwide.
Christopher Hitchens (13 April 1949 – 15 December 2011) was a British and American author, polemicist, debater and journalist who in his youth took part in demonstrations against the Vietnam War, joined organisations such as the International Socialists while at university and began to identify as a socialist. However, after 9/11 he no longer regarded himself as a socialist and his political thinking became largely dominated by the issue of defending civilization from terrorists and against the totalitarian regimes that protect them. Hitchens nonetheless continued to identify as a Marxist, endorsing the materialist conception of history, but believed that Karl Marx had underestimated the revolutionary nature of capitalism. He sympathized with libertarian ideals of limited state interference, but considered libertarianism not to be a viable system. In the 2000 U.S. presidential election, he supported the Green Party candidate Ralph Nader. After 9/11, Hitchens advocated for the invasion of Iraq. In the 2004 election, he very slightly favored the incumbent Republican President George W. Bush or was neutral and in 2008 he favored the Democratic candidate Barack Obama over John McCain despite being critical of both of them.
Southern Ohio Medical Center (or SOMC) is a 216-bed 501(C)(3) not-for-profit hospital in Portsmouth, Ohio. It provides emergency and surgical care, as well as other health care services. SOMC employs 2,600 full-time employees and part-time employees, has a medical staff of more than 140 physicians and specialists, and is supported by approximately 800 volunteers. In 2020, Fortune magazine ranked Southern Ohio Medical Center at number 22 of their Fortune List of the Top 100 Companies to Work For based on an employee survey of satisfaction.
Cube sugar (sometimes called sugar lumps) are white or brown granulated sugars lightly steamed and pressed together in block shape. They are used to sweeten drinks. Sugarloaf was the usual cone-form in which refined sugar was produced and sold until the late 19th century.
Sources: en.wikipedia.org
=== Combination ESG and pharmacologic therapy === ESG can safely be combined with weight loss medications to improve weight loss or prevent weight regain after the procedure. The daily injectable medication liraglutide showed greater total body weight loss when combined with ESG compared to ESG alone at 7 months (approximately 25% vs 20% respectively). Similar results are anticipated with other incretin agents, such as semaglutide and tirzepatide, though no studies have directly assessed these combinations.
Robertson had been rejected as a candidate for the chair in physiology at Johns Hopkins University because his reputation had been "tarnished" not only by his decision to patent tethelin, but also by his association with its potential commercial exploitation. Robertson also learned that his long post-graduate association with American universities — rather than the (preferred at the time) post-graduate work in United Kingdom — had caused his application to join the newly founded Walter and Eliza Hall Institute of Research in Pathology and Medicine, as its first Director, to be rejected in favour of the successful candidate, Sydney W. Patterson M.B. B.S., M.D., D.Sc., who had studied in the UK at University College London, and had gained his Doctor of Science (D.Sc.) from the University of London. With a desire to return to Australia — and hoping to apply his acquired academic, administrative, and research skills, talents, and expertise to Australian circumstances — he accepted (in June 1919) the University of Adelaide's (April 1919) offer of a Chair, vacant since the (20 March 1919) death of Robertson's father-in-law, Sir Edward Stirling, who had been the university's Professor of Physiology; and, where, in the interim, Charles Kellaway, M.B. B.S., M.D., M.S. of Melbourne, had served as locum.
Septoplasty is a corrective surgical procedure for nasal septum deviation in which the nasal septum is straightened. Tonsillectomy or adenoidectomy in an attempt to increase the size of the airway. Tonsillotomy Removal or reduction of parts of the soft palate and some or all of the uvula, such as uvulopalatopharyngoplasty (UPPP) or laser-assisted uvulopalatoplasty (LAUP). Modern variants of this procedure sometimes use radiofrequency waves to heat and remove tissue. Turbinectomy is a surgical procedure in which all or some of the turbinate bones are removed to relieve nasal obstruction. Reduction of the tongue base, either with laser excision or radiofrequency ablation. Genioglossus advancement, in which a small portion of the lower jaw that attaches to the tongue is moved forward, to pull the tongue away from the back of the airway. Hyoid suspension, in which the hyoid bone in the neck, another attachment point for tongue muscles, is pulled forward in front of the larynx. Maxillomandibular advancement Bariatric surgery (for morbid obesity) Hypoglossal nerve stimulation Radiofrequency ablation
=== Pharmacokinetics === The bioavailability of anastrozole in humans is unknown, but it was found to be well-absorbed in animals. Absorption of anastrozole is linear over a dosage range of 1 to 20 mg/day in humans and does not change with repeated administration. Food does not significantly influence the extent of absorption of anastrozole. Peak levels of anastrozole occur a median 3 hours after administration, but with a wide range of 2 to 12 hours. Steady-state levels of anastrozole are achieved within 7 to 10 days of continuous administration, with 3.5-fold accumulation. However, maximal suppression of estradiol levels occurs within 3 or 4 days of therapy. Active efflux of anastrozole by P-glycoprotein at the blood–brain barrier has been found to limit the central nervous system penetration of anastrozole in rodents, whereas this was not the case with letrozole and vorozole. As such, anastrozole may have peripheral selectivity in humans, although this has yet to be confirmed. In any case, estradiol is synthesized peripherally and readily crosses the blood–brain barrier, so anastrozole would still expected to reduce estradiol levels in the central nervous system to a certain degree. The plasma protein binding of anastrozole is 40%. The metabolism of anastrozole is by N-dealkylation, hydroxylation, and glucuronidation. Inhibition of aromatase is due to anastrozole itself rather than to metabolites, with the major circulating metabolite being inactive. The elimination half-life of anastrozole is 40 to 50 hours (1.7 to 2.1 days).
According to US Chamber of Commerce 70% of all illicit drug users are employed. Some industries have high rates of employee drug use such as construction (12.8%), repair (11.1%), and hospitality (7.9-16.3%).
Sources: en.wikipedia.org
Liquid chromatography-tandem mass spectrometry is a common approach. It can detect the parent compound and its metabolites in biological matrices.
Research samples are typically kept frozen, desiccated, and protected from light. Stock solutions are often aliquoted to reduce freeze-thaw cycles.
High-performance liquid chromatography and nuclear magnetic resonance are standard for purity and identity. Mass spectrometry confirms molecular weight.
SR9009 is a synthetic research compound that binds and modulates the nuclear receptors REV-ERBα and REV-ERBβ. It is used in laboratory studies of circadian biology and metabolism, not as an approved medicine. It is also known by the informal name Stenabolic.